Pneumococcal conjugate vaccine (PCV) 2024
A Contract Award Notice
by SECRETARY OF STATE FOR HEALTH AND SOCIAL CARE ACTING AS PART OF THE CROWN THROUGH UK HEALTH SECURITY AGENCY
- Source
- Find a Tender
- Type
- Contract (Supply)
- Duration
- 4 year (est.)
- Value
- £1
- Sector
- HEALTH
- Published
- 15 Feb 2024
- Delivery
- 01 Aug 2024 to 31 Jul 2028 (est.)
- Deadline
- n/a
Concepts
Location
Lutterworth, UK
2 buyers
1 supplier
- Pfizer Kent
Description
Contract for the supply of pneumococcal conjugate vaccine (PCV)
Total Quantity or Scope
A contract for a vaccine to protect against invasive Pneumococcal disease, to be used as part of the national childhood immunisation programme.Deliveries will be required over a period of 2 years, with an option to extend for up to an additional 24 months.
Award Detail
1 | Pfizer (Kent)
|
Renewal Options
The contract has the option to be extended for up to an additional 24 months
Award Criteria
Clinical benefit | _ |
Adjusting for doses which are not administered to individuals | _ |
Programme risk | _ |
Social value | _ |
Administration costs | _ |
Risk mitigation costs | _ |
Vaccine price | _ |
Storage cost | _ |
CPV Codes
- 33651600 - Vaccines
Indicators
- Options are available.
Other Information
Value — The value has been withheld so as not to prejudice the legitimate commercial interest of the supplier. The contract is for the benefit of the contracting authority and NHS bodies along with any other non-NHS bodies which are necessary for the delivery of services or goods to NHS bodies, local authorities, other government departments and their executive agencies or non-departmental public bodies charged with the delivery of healthcare or health related services in the United Kingdom, Crown Dependencies and British Overseas Territories including, without limitation, the National Assembly for Wales, the Northern Ireland Assembly, and Scottish Ministers. The resulting products delivered against the contract may be made available to the UK devolved administrations, Crown Dependencies and British Overseas Territories to undertake their respective vaccination programmes.
Reference
- FTS 005110-2024